

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6142297

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ADIMAB LLC	10/16/2018
RECEIVING PARTY DATA		
Name:	COMPASS THERAPEUTICS LLC	
Street Address:	245 FIRST STREET, 3RD FLOOR	
City:	CAMBRIDGE	
State/Country:	MASSACHUSETTS	
Postal Code:	02142	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16895239
CORRESPONDENCE DATA		
Fax Number:	(978)448-8721	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	978-448-8720	
Email:	DOCKETING@DTWARDLAW.COM	
Correspondent Name:	DT WARD, PC	
Address Line 1:	142A MAIN STREET	
Address Line 4:	GROTON, MASSACHUSETTS 01450	
ATTORNEY DOCKET NUMBER:	2183.1008USDIV4	
NAME OF SUBMITTER:	JESSICA L. CHARLAND	
SIGNATURE:	/Jessica L. Charland/	
DATE SIGNED:	06/08/2020	
Total Attachments: 4		
source=CTX-010USCON1DIV4 (2183.1008USDIV4) ASSIGNMENT_Adimab To Compass#page1.tif		
source=CTX-010USCON1DIV4 (2183.1008USDIV4) ASSIGNMENT_Adimab To Compass#page2.tif		
source=CTX-010USCON1DIV4 (2183.1008USDIV4) ASSIGNMENT_Adimab To Compass#page3.tif		
source=CTX-010USCON1DIV4 (2183.1008USDIV4) ASSIGNMENT_Adimab To Compass#page4.tif		

ASSIGNMENT

We, Adimab LLC, of Lebanon, New Hampshire, respectively, for good and valuable consideration paid to it by

Compass Therapeutics LLC

a Limited Liability Company of Delaware, having its principal place of business at 245 First Street, Third Floor, Cambridge, Massachusetts 02142, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said

Compass Therapeutics LLC

its successors and assigns, the entire interest for the United States of America and all foreign countries including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in

AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF

described in an application

☐ Executed by us of even date herewith and about to be filed

or

☒ Application No. 16/032,639, filed on July 11, 2018; and International Application No. PCT/US2018/041612, filed on July 11, 2018

This application claims the benefit of the following provisional application(s):

☒ Provisional Application No. 62/577259, filed on October 26, 2017
Provisional Application No. 62/577257, filed on October 26, 2017
Provisional Application No. 62/568231, filed on October 4, 2017
Provisional Application No. 62/531259, filed on July 11, 2017
Provisional Application No. 62/531190, filed on July 11, 2017

in the United States Patent and Trademark Office, and in all Letters Patent of the United States and all foreign countries which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuing, reissue or other applications based in whole or in part thereon. And ASSIGNOR agrees, with said Limited Liability Company and its successors and assigns but at its expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said Limited Liability Company, with specifications and claims in such form as shall be approved by the counsel of said Limited Liability Company and to vest and confirm in said Limited Liability Company, its successors and assigns, the legal title to all such patents.

PATENT

REEL: 052865 FRAME: 0600

And ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said Limited Liability Company, its successors and assigns.

And ASSIGNOR further hereby grants the attorneys/agents of Nelson Mullins Riley & Scarborough LLP, the power to insert on this Assignment the filing date and/or application number of said application.


ASSIGNOR:

ERIC KRAULAND

Signatory Name (print)

CHIEF SCIENTIFIC OFFICER


Signatory Title (print)



Signature, Adimab LLC

Date: October 16th 2018

Witness:



Signature

10/16/18

Date

ASSIGNEE:

I hereby acknowledge that rights in the above-identified application have transferred from the assignor(s) by virtue of their above execution of this Assignment and are hereby conveyed to Compass Therapeutics LLC, the Assignee, of which I am an authorized signatory.

JAMON BANKS

Signatory Name (print)

VP, LEGAL AFFAIRS

Signatory Title (print)

[Signature]
Signature, Compass Therapeutics LLC

Date:

10/23/18

Witness:

10/23/18[Signature]